289 related articles for article (PubMed ID: 34907087)
1. Runx2 Deficiency in Osteoblasts Promotes Myeloma Resistance to Bortezomib by Increasing TSP-1-Dependent TGFβ1 Activation and Suppressing Immunity in Bone Marrow.
Zhang C; Xu X; Trotter TN; Gowda PS; Lu Y; Suto MJ; Javed A; Murphy-Ullrich JE; Li J; Yang Y
Mol Cancer Ther; 2022 Feb; 21(2):347-358. PubMed ID: 34907087
[TBL] [Abstract][Full Text] [Related]
2. Runx2 Deficiency in Osteoblasts Promotes Myeloma Progression by Altering the Bone Microenvironment at New Bone Sites.
Xu X; Zhang C; Trotter TN; Gowda PS; Lu Y; Ponnazhagan S; Javed A; Li J; Yang Y
Cancer Res; 2020 Mar; 80(5):1036-1048. PubMed ID: 31911552
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of Transforming Growth Factor-β Activation Diminishes Tumor Progression and Osteolytic Bone Disease in Mouse Models of Multiple Myeloma.
Lu A; Pallero MA; Lei W; Hong H; Yang Y; Suto MJ; Murphy-Ullrich JE
Am J Pathol; 2016 Mar; 186(3):678-90. PubMed ID: 26801735
[TBL] [Abstract][Full Text] [Related]
4. A Hyaluronan and Proteoglycan Link Protein 1 Matrikine: Role of Matrix Metalloproteinase 2 in Multiple Myeloma NF-κB Activation and Drug Resistance.
Mark C; Warrick J; Callander NS; Hematti P; Miyamoto S
Mol Cancer Res; 2022 Sep; 20(9):1456-1466. PubMed ID: 35604822
[TBL] [Abstract][Full Text] [Related]
5. Gfi1 expressed in bone marrow stromal cells is a novel osteoblast suppressor in patients with multiple myeloma bone disease.
D'Souza S; del Prete D; Jin S; Sun Q; Huston AJ; Kostov FE; Sammut B; Hong CS; Anderson JL; Patrene KD; Yu S; Velu CS; Xiao G; Grimes HL; Roodman GD; Galson DL
Blood; 2011 Dec; 118(26):6871-80. PubMed ID: 22042697
[TBL] [Abstract][Full Text] [Related]
6. Tumour-associated macrophage-mediated survival of myeloma cells through STAT3 activation.
De Beule N; De Veirman K; Maes K; De Bruyne E; Menu E; Breckpot K; De Raeve H; Van Rampelbergh R; Van Ginderachter JA; Schots R; Van Valckenborgh E; Vanderkerken K
J Pathol; 2017 Mar; 241(4):534-546. PubMed ID: 27976373
[TBL] [Abstract][Full Text] [Related]
7. Tipifarnib and bortezomib are synergistic and overcome cell adhesion-mediated drug resistance in multiple myeloma and acute myeloid leukemia.
Yanamandra N; Colaco NM; Parquet NA; Buzzeo RW; Boulware D; Wright G; Perez LE; Dalton WS; Beaupre DM
Clin Cancer Res; 2006 Jan; 12(2):591-9. PubMed ID: 16428505
[TBL] [Abstract][Full Text] [Related]
8. Exosomes play a role in multiple myeloma bone disease and tumor development by targeting osteoclasts and osteoblasts.
Faict S; Muller J; De Veirman K; De Bruyne E; Maes K; Vrancken L; Heusschen R; De Raeve H; Schots R; Vanderkerken K; Caers J; Menu E
Blood Cancer J; 2018 Nov; 8(11):105. PubMed ID: 30409995
[TBL] [Abstract][Full Text] [Related]
9. Blocking of Transient Receptor Potential Vanilloid 1 (TRPV1) promotes terminal mitophagy in multiple myeloma, disturbing calcium homeostasis and targeting ubiquitin pathway and bortezomib-induced unfolded protein response.
Beider K; Rosenberg E; Dimenshtein-Voevoda V; Sirovsky Y; Vladimirsky J; Magen H; Ostrovsky O; Shimoni A; Bromberg Z; Weiss L; Peled A; Nagler A
J Hematol Oncol; 2020 Nov; 13(1):158. PubMed ID: 33239060
[TBL] [Abstract][Full Text] [Related]
10. Combined treatment with a transforming growth factor beta inhibitor (1D11) and bortezomib improves bone architecture in a mouse model of myeloma-induced bone disease.
Nyman JS; Merkel AR; Uppuganti S; Nayak B; Rowland B; Makowski AJ; Oyajobi BO; Sterling JA
Bone; 2016 Oct; 91():81-91. PubMed ID: 27423464
[TBL] [Abstract][Full Text] [Related]
11. Runx2 Suppression by miR-342 and miR-363 Inhibits Multiple Myeloma Progression.
Gowda PS; Wildman BJ; Trotter TN; Xu X; Hao X; Hassan MQ; Yang Y
Mol Cancer Res; 2018 Jul; 16(7):1138-1148. PubMed ID: 29592898
[TBL] [Abstract][Full Text] [Related]
12. The proteasome inhibitor bortezomib inhibits FGF-2-induced reduction of TAZ levels in osteoblast-like cells.
Eda H; Aoki K; Kato S; Okawa Y; Takada K; Tanaka T; Marumo K; Ohkawa K
Eur J Haematol; 2010 Jul; 85(1):68-75. PubMed ID: 20192985
[TBL] [Abstract][Full Text] [Related]
13. Resensitising proteasome inhibitor-resistant myeloma with sphingosine kinase 2 inhibition.
Bennett MK; Li M; Tea MN; Pitman MR; Toubia J; Wang PP; Anderson D; Creek DJ; Orlowski RZ; Gliddon BL; Powell JA; Wallington-Beddoe CT; Pitson SM
Neoplasia; 2022 Jan; 24(1):1-11. PubMed ID: 34826777
[TBL] [Abstract][Full Text] [Related]
14. XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of IκBα and overcomes acquired proteasome inhibitor resistance in human multiple myeloma.
Turner JG; Kashyap T; Dawson JL; Gomez J; Bauer AA; Grant S; Dai Y; Shain KH; Meads M; Landesman Y; Sullivan DM
Oncotarget; 2016 Nov; 7(48):78896-78909. PubMed ID: 27806331
[TBL] [Abstract][Full Text] [Related]
15. Myeloma cells block RUNX2/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation.
Giuliani N; Colla S; Morandi F; Lazzaretti M; Sala R; Bonomini S; Grano M; Colucci S; Svaldi M; Rizzoli V
Blood; 2005 Oct; 106(7):2472-83. PubMed ID: 15933061
[TBL] [Abstract][Full Text] [Related]
16. The novel β2-selective proteasome inhibitor LU-102 synergizes with bortezomib and carfilzomib to overcome proteasome inhibitor resistance of myeloma cells.
Kraus M; Bader J; Geurink PP; Weyburne ES; Mirabella AC; Silzle T; Shabaneh TB; van der Linden WA; de Bruin G; Haile SR; van Rooden E; Appenzeller C; Li N; Kisselev AF; Overkleeft H; Driessen C
Haematologica; 2015 Oct; 100(10):1350-60. PubMed ID: 26069288
[TBL] [Abstract][Full Text] [Related]
17. Bortezomib-induced pro-inflammatory macrophages as a potential factor limiting anti-tumour efficacy.
Beyar-Katz O; Magidey K; Ben-Tsedek N; Alishekevitz D; Timaner M; Miller V; Lindzen M; Yarden Y; Avivi I; Shaked Y
J Pathol; 2016 Jul; 239(3):262-73. PubMed ID: 27037906
[TBL] [Abstract][Full Text] [Related]
18. The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients.
Giuliani N; Morandi F; Tagliaferri S; Lazzaretti M; Bonomini S; Crugnola M; Mancini C; Martella E; Ferrari L; Tabilio A; Rizzoli V
Blood; 2007 Jul; 110(1):334-8. PubMed ID: 17371942
[TBL] [Abstract][Full Text] [Related]
19. TGFβ Inhibition Stimulates Collagen Maturation to Enhance Bone Repair and Fracture Resistance in a Murine Myeloma Model.
Green AC; Lath D; Hudson K; Walkley B; Down JM; Owen R; Evans HR; Paton-Hough J; Reilly GC; Lawson MA; Chantry AD
J Bone Miner Res; 2019 Dec; 34(12):2311-2326. PubMed ID: 31442332
[TBL] [Abstract][Full Text] [Related]
20. Syrbactin proteasome inhibitor TIR-199 overcomes bortezomib chemoresistance and inhibits multiple myeloma tumor growth in vivo.
Pierce MR; Robinson RM; Ibarra-Rivera TR; Pirrung MC; Dolloff NG; Bachmann AS
Leuk Res; 2020 Jan; 88():106271. PubMed ID: 31778912
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
